| 1) 33 providing data on risk and protective factors and 18 providing only prevalence d |
| 2) EPAs (n = 11,37.9%); (3) examining the factors and barriers that influence the im |
| 3) understanding of the link between social factors and cerebrovascular disease will b |
| 4) Objective: To identify patient-related factors and characteristics of PILs that c |
| 5) gulatory programs involving transcription factors and chromatin modulators. |
| 6) iodontal diseases and COVID-19; (ii) risk factors and comorbidities common to period |
| 7) e delivery, including addressing upstream factors and comorbidities impacting skin h |
| 8) in children and highlights important risk factors and comorbidities. |
| 9) arable clinical evidence in terms of risk factors and complications, challenges pres |
| 10) heir expression of specific transcription factors and cytokines1. |
| 11) o understand the nature of the major risk factors and design features of a safe and |
| 12) the association between built environment factors and dietary intake, physical activ |
| 13) the association between built environment factors and dietary intake, physical activ |
| 14) iations between physical or psychological factors and either walking capacity, gait |
| 15) on facilitators (category 2: motivational factors and exercising effects). |
| 16) f the categories of the psychosocial risk factors and hazards affecting HCWs during |
| 17) Overall, the key diet-related risk factors and health outcomes were modeled, |
| 18) We discuss the challenges of contextual factors and highlight innovation needs. |
| 19) ions between several colostrum management factors and immunological colostrum qualit |
| 20) to food insecurity, but the contributing factors and impacts of this issue were ins |
| 21) iations between physical or psychological factors and impaired walking capacity in p |
| 22) arch has been undertaken to identify risk factors and intervention methods to decrea |
| 23) hart all available literature on the risk factors and interventions associated with |
| 24) The risk factors and interventions pertaining to ta |
| 25) Poor socioeconomic factors and low educational background wer |
| 26) /mTOR pathways and supresses inflammatory factors and mediators such as IL-1β, IL-6 |
| 27) niform framework that specifies different factors and metrics for the evaluation is |
| 28) Strengthening protective factors and minimizing the impact of risk |
| 29) data provide further insight into genetic factors and pathways involved in PTSD, as |
| 30) be used to improve understandings of risk factors and pathways. |
| 31) ginating from both patient/family-related factors and physician/health system compon |
| 32) In this review, we discuss the GIT factors and physicochemical and biological |
| 33) combined stressor exposures and personal factors and risk to foster methods for occ |
| |